The design and performance of the exubera pulmonary insulin delivery system

• Published in: Diabetes technology & therapeutics Vol. 9 Suppl 1; p. S16
• Main Authors: Harper, Nancy J, Gray, Steven, De Groot, Jennifer, Parker, Joann M, Sadrzadeh, Negar, Schuler, Carlos, Schumacher, Jacqueline D, Seshadri, Sangita, Smith, Adrian E, Steeno, Gregory S, Stevenson, Cynthia L, Taniere, Romain, Wang, May, Bennett, David B
• Format: Journal Article
• Language: English
• Published: United States 01.06.2007
• Subjects: Administration, Inhalation; Aerosols; Equipment Design; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - pharmacokinetics; Hypoglycemic Agents - therapeutic use; Insulin - administration & dosage; Insulin - pharmacokinetics; Insulin - therapeutic use; Lung - physiology; Thermodynamics; Treatment Outcome
• ISSN: 1520-9156
• DOI: 10.1089/dia.2007.0222

The Exubera system (Pfizer, New York, NY/Nektar Therapeutics, San Carlos, CA) is an integration of five major new technologies: protein formulation, powder processing, powder filling, drug packaging, and delivery device. The product provides a simple interface, where the patient interacts only with the delivery device and powder packaging. These components were designed together to assure repeatable dosing when used by a wide range of patients under real-world life-style and handling conditions. The device design is purely mechanical, using patient-generated compressed air as the energy source. Upon actuation, a sonic discharge of air through the novel release unit reproducibly extracts, de-agglomerates, and disperses the inhalation powder into a respirable aerosol. A clear holding chamber allows for patient feedback via dose visualization and separates aerosol cloud generation from the inspiratory effort. The Exubera product was tested under a wide range of typical use conditions and potential misuse scenarios and following long-term usage in clinical trials. These comprehensive characterization programs demonstrated robust aerosol and mechanical performance, confirming the design intent of the inhaler. These studies provide assurance of consistent and reliable dose delivery in a real-world use of the product.